Media coverage about Intercept Pharmaceuticals (NASDAQ:ICPT) has been trending positive on Friday, according to Alpha One Sentiment Analysis. Alpha One, a division of Accern, identifies negative and positive media coverage by analyzing more than twenty million blog and news sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a coverage optimism score of 0.39 on Alpha One’s scale. Alpha One also gave press coverage about the biopharmaceutical company an impact score of 68 out of 100, meaning that recent media coverage is likely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected AlphaOne’s rankings:
- Intercept Receives Innovation Award from the National Organization for Rare Disorders for the Development of Ocaliva® (obeticholic acid) (finance.yahoo.com)
- Intercept Pharmaceuticals Inc (ICPT) Insider Sells $13,530.62 in Stock (americanbankingnews.com)
- Intercept Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ICPT-US : May 18, 2017 (finance.yahoo.com)
- FBR & Co Comments on Intercept Pharmaceuticals Inc’s Q2 2017 Earnings (ICPT) (americanbankingnews.com)
- Intercept to Present at Upcoming Conferences (finance.yahoo.com)
Several research analysts have recently weighed in on ICPT shares. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, April 12th. Wedbush reaffirmed an “outperform” rating and issued a $224.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, March 17th. Needham & Company LLC cut shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 20th. Cowen and Company reiterated a “buy” rating and issued a $225.00 target price on shares of Intercept Pharmaceuticals in a research report on Monday, April 24th. Finally, Robert W. Baird reiterated a “positive” rating on shares of Intercept Pharmaceuticals in a research report on Friday, February 10th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Intercept Pharmaceuticals has an average rating of “Buy” and a consensus target price of $188.37.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.35% during trading on Friday, hitting $115.54. 158,387 shares of the company’s stock were exchanged. The stock’s market cap is $2.89 billion. The firm has a 50-day moving average price of $112.40 and a 200-day moving average price of $113.04. Intercept Pharmaceuticals has a one year low of $96.63 and a one year high of $177.93.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($3.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($4.27) by $0.66. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The firm had revenue of $21 million for the quarter, compared to the consensus estimate of $15.88 million. During the same period in the prior year, the firm posted ($5.17) earnings per share. The firm’s quarterly revenue was up 4566.7% compared to the same quarter last year. Equities research analysts expect that Intercept Pharmaceuticals will post ($14.65) EPS for the current fiscal year.
In other Intercept Pharmaceuticals news, CMO David Shapiro sold 558 shares of the stock in a transaction dated Monday, April 10th. The shares were sold at an average price of $108.51, for a total transaction of $60,548.58. Following the completion of the transaction, the chief marketing officer now owns 45,465 shares of the company’s stock, valued at $4,933,407.15. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Lisa Bright sold 254 shares of the firm’s stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $119.48, for a total transaction of $30,347.92. Following the completion of the transaction, the insider now directly owns 21,695 shares of the company’s stock, valued at approximately $2,592,118.60. The disclosure for this sale can be found here. Insiders have sold 3,318 shares of company stock valued at $375,832 over the last 90 days. 9.20% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Favorable Media Coverage Likely to Impact Intercept Pharmaceuticals (ICPT) Share Price” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/05/19/intercept-pharmaceuticals-icpt-given-coverage-optimism-score-of-0-39-updated-updated.html.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.